

Immuron appoints Steven Lydeamore as Chief Executive Officer

06 May 2022 | News

Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA.



Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, has announced the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the company effective 27 June 2022.

Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This includes valuable experience in mergers and acquisitions, finance, business development, sales and marketing, manufacturing, and research and development.

He was most recently Chief Executive Officer (CEO) of Anantara Lifesciences Limited, during which time the company successfully transitioned from a preclinical to a clinical company following development of a gastrointestinal tract delivery technology from which two products have commenced human clinical trials.

Upon Lydeamore's appointment Dr. Jerry Kanellos, who has been interim CEO for the last two years will resume the role of Chief Operating Officer.